Stocks · Healthcare · Medical - Devices
Bioventus Inc. BVS
$13.13 -2.38% Close, Oct 2, 2026 · NASDAQ · Market cap $889.5M
High qualityStrong trendInexpensive vs sector
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Over the past year the stock returned +95.7%, ahead of the S&P 500 by 80.6 percentage points.
- The stock is in an uptrend: above its 200-day average for 86 trading days, with the 50-day average above the 200-day.
- Operating margin widened to 10.6% from 6.3% a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 35%
- FCF growth (TTM, YoY)Top 8%
- Revenue growth, 3-year CAGRBottom 33%
- Revenue growth accelerationTop 31%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 12%
- Gross marginTop 45%
- Operating marginTop 25%
- Cash conversion (OCF / net income)Top 39%
- Accruals (lower is better)Bottom 49%
- Net debt / EBITDA (lower is better)Bottom 35%
- Interest coverTop 32%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 8%
- Free-cash-flow yieldTop 7%
- EBITDA / enterprise valueTop 12%
- Sales / enterprise valueTop 25%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 14%
- 6-month returnTop 21%
- 1-year return vs S&P 500Top 16%
- Distance from 52-week highTop 27%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 35%
- Consecutive EPS beatsTop 25%
- Share of analysts rating BuyBottom 41%
- Upside to consensus price targetBottom 40%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 40%
- Maximum drawdown, 3 yearsTop 29%
- Beta vs S&P 500 (lower is better)Top 20%
- Net debt / EBITDA (lower is better)Bottom 35%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 1.5% | 3.1% | ↑ |
| Gross margin | 67.1% | 68.0% | ↑ |
| Operating margin | 6.3% | 10.6% | ↑ |
| FCF margin | 6.0% | 16.2% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 3.1% | 1.5% | ↑ | Bottom 35% |
| Gross margin | 68.0% | 67.1% | ↑ | Top 45% |
| Operating margin | 10.6% | 6.3% | ↑ | Top 25% |
| Net margin | 9.4% | -0.0% | ↑ | — |
| Free-cash-flow margin | 16.2% | 6.0% | ↑ | — |
| Return on invested capital | 11.4% | — | Top 12% | |
| Revenue growth, 3-year CAGR | 3.5% | — | Bottom 33% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.78×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -6.3%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 2.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +1.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 2.52×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 3.1×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.18%
- Shareholder yield
- -0.18%
- Share count change, 1 year
- +3.4%
- Share count change, 3-year CAGR
- +4.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 27, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 3
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +11.8%
- Average 2-day reaction, last 8
- +6.6%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $18.33
- Target vs current price
- +39.6%
- Analysts with a rating
- 7
- Share rating Buy or Strong Buy
- 71%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +1.7% | +13.7% | +3.2% | +1.9% | — |
| May 6, 2026 | +66.7% | +2.2% | -5.1% | -19.9% | +23.3% |
| Mar 5, 2026 | +9.1% | +7.4% | +5.1% | +8.0% | +0.5% |
| Nov 4, 2025 | -30.2% | +15.1% | +14.2% | +15.2% | +20.9% |
| Aug 6, 2025 | -4.5% | +18.7% | +19.1% | +14.7% | +10.3% |
| May 6, 2025 | +33.3% | -11.8% | -4.1% | -5.3% | -7.3% |
| Mar 11, 2025 | +87.5% | +23.3% | +11.9% | -5.6% | -25.5% |
| Nov 5, 2024 | +0.0% | -16.3% | -9.3% | -13.8% | -23.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | $0.22 | $0.22 | +1.7% | $153.2M |
| May 6, 2026 | $0.15 | $0.09 | +66.7% | $132.1M |
| Mar 5, 2026 | $0.24 | $0.22 | +9.1% | $157.9M |
| Nov 4, 2025 | $0.15 | $0.22 | -30.2% | $138.7M |
| Aug 6, 2025 | $0.21 | $0.22 | -4.5% | $147.7M |
| May 6, 2025 | $0.08 | $0.06 | +33.3% | $123.9M |
| Mar 11, 2025 | $0.15 | $0.08 | +87.5% | $153.6M |
| Nov 5, 2024 | $0.06 | $0.06 | +0.0% | $139.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 17.0× | — | — | Top 8% |
| P/E (forward) | 16.9× | — | — | — |
| EV / EBITDA | 12.1× | — | — | Top 12% |
| EV / Sales | 1.93× | — | — | Top 25% |
| Free-cash-flow yield | 10.60% | — | — | Top 7% |
| Earnings yield | 5.87% | — | — | Top 8% |
P/E over the past five years
Range 19.8× – 66.3× since Jul 3, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 86
- 50-day average slope (20 days)
- +6.8%
- 200-day average slope (20 days)
- +6.3%
- Distance from 50-day average
- -3.9%
- Distance from 200-day average
- +27.7%
- RSI (14)
- 44.2
- Relative volume
- 0.75×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 49.9%
- Volatility vs own 5-year history
- 21th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.58
- Correlation with S&P 500
- 0.21
- Current drawdown from 1-year high
- -14.0%
- Maximum drawdown, 3 years
- -55.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 11, 2021 | May 4, 2023 | -95.2% | 560 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $889.5M
- P/E (TTM)
- 17.0
- EPS, diluted (TTM)
- $0.77
- Revenue (TTM)
- $581.8M
- 52-week range
- $6.37 – $15.89
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $430.9M | $512.1M | $512.3M | $573.3M | $568.1M |
| Gross profit | $302.7M | $331.1M | $328.2M | $388.2M | $382.4M |
| Operating income | $12.1M | -$167.2M | -$81.7M | -$12.0M | $58.5M |
| Net income | $19.4M | -$158.7M | -$156.2M | -$33.5M | $22.7M |
| EPS (diluted) | $0.43 | -$2.59 | -$2.49 | -$0.52 | $0.33 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $139.0M | $153.6M | $123.9M | $147.7M | $138.7M | $157.9M | $132.1M | $153.2M |
| Net income | -$4.8M | -$156,000 | -$2.6M | $7.5M | $3.2M | $14.8M | $3.1M | $33.4M |
| EPS (diluted) | -$0.07 | -$0.00 | -$0.04 | $0.11 | $0.05 | $0.21 | $0.04 | $0.47 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $23.0M | -$13.5M | $15.3M | $38.8M | $74.0M |
| Capital expenditure | -$20.9M | -$1.5M | -$7.4M | -$1.0M | -$2.6M |
| Free cash flow | $2.1M | -$15.0M | $8.0M | $37.8M | $71.4M |
| Dividends paid | -$367,000 | $0 | $0 | $0 | $0 |
| Net share buybacks | $109.4M | $5.8M | $778,000 | $2.4M | $2.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $29.5M
- Total assets
- $673.3M
- Total liabilities
- $395.9M
- Total debt
- $263.7M
- Net debt
- $234.3M
- Shareholders’ equity
- $228.3M
As of Jun 27, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 2,930,690
- Days to cover
- 5.73
- Change vs previous report
- +13.6%
FINRA short interest, settlement date Sep 15, 2026.